Soft Tissue Sarcoma - Pipeline Insight, 2021

Soft Tissue Sarcoma - Pipeline Insight, 2021

  • May 2021 •
  • 240 pages •
  • Report ID: 5028187 •
  • Format: PDF
“Soft Tissue Sarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Soft Tissue Sarcoma Understanding

Soft Tissue Sarcoma: Overview
Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. There are more than 50 different types of soft tissue sarcomas, which can develop in many different locations and tissues within the body. The signs and symptoms of STS vary greatly from patients to patients based on the type of STS. The majority of high-grade sarcomas with complex karyotypes have a high frequency of protein 53 (p53) and retinoblastoma protein (pRb) mutations as well as impairments in DNA repair and severe chromosomal instability, but no specific genetic alterations. Patients with soft-tissue sarcomas present with a mass that generally is increasing in size. The location and depth of the mass can be assessed on physical examination. The diagnosis of STSs is mainly done by doing Imaging tests and by biopsy. Treatments for soft tissue sarcoma typically involve surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of two or more of these approaches.

"Soft Tissue Sarcoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided which includes the disease overview and Soft Tissue Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Soft Tissue Sarcoma.

Soft Tissue Sarcoma Emerging Drugs Chapters
This segment of the Soft Tissue Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Soft Tissue Sarcoma Emerging Drugs

• AL-3818: Advenchen Laboratories
AL3818 is a novel small molecule dual receptor tyrosine kinase inhibitor, which shows highly selective inhibition of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR). Advenchen Laboratories, LLC is developing AL-3818 for the treatment of patients with advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), synovial sarcoma (SS), and soft-tissue sarcoma (STS). The drug is currently in the Phase III stage of development.

• Fibromun: Philogen
Fibromun is a fully human recombinant fusion protein being developed by Philogen for the treatment of cancer, including gliomas, glioblastoma. It is a human antibody-cytokine fusion protein consisting of the non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin (L19) in the single-chain variable fragment (scFv) format. The antibody-TNF fusion protein selectively localizes to tumor lesions following systemic administration. It is currently being studied in Phase III and Phase II of clinical development to treat STS patients in Europe and the United States, respectively.
Further product details are provided in the report……..

Soft Tissue Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Soft Tissue Sarcoma
There are approx. 100+ key companies which are developing the therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Advenchen Laboratories.

• Phases
This report covers around 130+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Soft Tissue Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Soft Tissue Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Soft Tissue Sarcoma drugs.

Soft Tissue Sarcoma Report Insights
• Soft Tissue Sarcoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Soft Tissue Sarcoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Soft Tissue Sarcoma drugs?
• How many Soft Tissue Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Soft Tissue Sarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Soft Tissue Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Advenchen Laboratories
• Philogen
• Gradalis
• Epizyme
• Eli Lilly and Company
• Chugai Pharma France
• CytRx
• Arog Pharmaceuticals
• Taiho Pharmaceutical
• NantCell
• Nanobiotix
• KaryoPharm Therapeutics
• Apexigen
• Monopar Therapeutics
• Lytix Biopharma
• Novartis
• Athenex
• Bristol Myers Squibb
• Merck sharp & Dohme Corp.
• Incyte Corporation
• Daiichi Sankyo
• AstraZeneca
• Pfizer
• NantPharma
• Iovance Biotherapeutics
• Agenus
• GlaxoSmithKline
• AVEO Pharmaceuticals
• Amgen
• Atara Biotherapeutics
• Bayer
• VasGene Therapeutics
• Mirati Therapeutics
• EMD Serono
• Novartis
• Adaptimmune
• PTC Therapeutics
• Hillstream BioPharma
• MedImmune
• AstraZeneca

Key Products
• AL-3818
• Fibromun
• Vigil
• Tazemetostat
• Olaratumab
• Doxorubicin
• Aldoxorubicin
• Crenolanib
• TAS-116
• Ganitumab
• Selinexor
• APX005M
• GPX-150
• LTX-315
• PDR001
• Oraxol
• Nivolumab
• Lenvatinib
• Ipilimumab
• INCMGA00012
• Efatutazone
• Durvalumab
• Crizotinib
• MK3475
• AMG337
• LN-145-S1
• AGEN2034
• Abemaciclib
• TSR-042
• Tivozanib
• Talimogene Laherparepvec (T-VEC)
• Tabelecleucel
• Regorafenib
• sEphB4-HSA
• Sitravatinib (MGCD516)
• M6620
• Letrozole
• ADP-A2M4
• PTC596
• HSB-114
• Tremelimumab
• Selumetinib